MIR8087: A Potential Drug Target and Biomarker for Melanoma (G102465881)

MIR8087: A Potential Drug Target and Biomarker for Melanoma

Melanoma is one of the most aggressive forms of skin cancer, with a high incidence rate and a poor prognosis. Despite advances in treatment, the survival rate for melanoma remains high, with a 5-year survival rate of only around 45%. Therefore, there is a significant need for new treatments and biomarkers to improve outcomes for patients.

MIR8087 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for melanoma. MIR8087 is a 24-kDa protein that is expressed in various tissues and organs, including skin, gut, and breast tissue. It is a promising candidate for drug targeting due to its unique structure and its expression pattern in cancer cells.

The identification of MIR8087 as a potential drug target and biomarker for melanoma was derived from a series of experiments using cell-based assays and bioinformatics analysis. First, researchers found that MIR8087 was highly expressed in melanoma tissues and that it was downregulated in response to chemotherapy. Second, they demonstrated that MIR8087 was involved in the regulation of cell proliferation and apoptosis, which are critical processes in the development and progression of cancer.

Furthermore, researchers found that MIR8087 was expressed in various types of melanoma, including melanoma types that are resistant to chemotherapy, indicating that it may have a common mechanism of action with other treatments. Additionally, they found that MIR8087 was associated with poor prognosis in melanoma patients, which further supports its potential as a biomarker.

To further validate the potential of MIR8087 as a drug target and biomarker for melanoma, researchers conducted a series of in vitro and in vivo experiments. In vitro, they found that MIR8087 was effective in inhibiting the growth of melanoma cells and that it caused cell apoptosis. In vivo, they found that MIR8087 was associated with poor survival rates in melanoma patients, as well as increased metastasis and invasion in melanoma tumors.

In conclusion, MIR8087 is a promising candidate for drug targeting and biomarker for melanoma. Its unique structure and expression pattern, as well as its involvement in the regulation of cell proliferation and apoptosis, make it an attractive target for small molecule inhibitors. Further studies are needed to confirm its potential as a drug and to determine its efficacy in clinical trials.

Protein Name: MicroRNA 8087

The "MIR8087 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR8087 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR8088 | MIR8089 | MIR8485 | MIR873 | MIR874 | MIR875 | MIR876 | MIR877 | MIR885 | MIR887 | MIR888 | MIR889 | MIR890 | MIR891A | MIR891B | MIR892A | MIR892B | MIR892C | MIR9-1 | MIR9-1HG | MIR9-2 | MIR9-3 | MIR9-3HG | MIR920 | MIR921 | MIR922 | MIR924 | MIR924HG | MIR92A1 | MIR92A2 | MIR92B | MIR93 | MIR933 | MIR934 | MIR935 | MIR936 | MIR937 | MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR941-5 | MIR942 | MIR943 | MIR944 | MIR95 | MIR96 | MIR98 | MIR99A | MIR99AHG | MIR99B | MIRLET7 | MIRLET7A1 | MIRLET7A2 | MIRLET7A3 | MIRLET7B | MIRLET7BHG | MIRLET7C | MIRLET7D | MIRLET7E | MIRLET7F1 | MIRLET7F2 | MIRLET7G | MIRLET7I | MIS12 | MIS12 complex | MIS18A | MIS18A-AS1 | MIS18BP1 | MISFA | MISP | MISP3 | MITD1 | MITF | Mitochondrial complex I assembly complex | Mitochondrial import inner membrane translocase 23 (TIM23) complex | Mitochondrial inner membrane protease complex | Mitochondrial membrane ATP synthase | Mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) | Mitochondrial pyruvate carrier complex (MPC) | Mitochondrial RNA processing endoribonuclease | Mitofilin Complex | Mitofusin | Mitogen-Activated Protein Kinase | Mitogen-activated protein kinase (JNK) | Mitogen-Activated Protein Kinase (MAP Kinase)-Activated Protein Kinase | Mitogen-Activated Protein Kinase Kinase Kinase (MAP3K) | Mitogen-activated protein kinase p38 (MAPK p38) | MITRAC complex | MIX23 | MIXL1 | MKI67 | MKKS | MKLN1 | MKLN1-AS | MKNK1 | MKNK1-AS1